Clinical Trial Update: Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness [Phase 3]

View source ↗

Summary

Extension Phase 3 study of armodafinil for excessive daytime sleepiness, including narcolepsy and related sleep disorders, completed with results posted in 2010…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Daytime Sleepiness
• Narcolepsy
• Obstructive Sleep Apnea
• Shift Work Sleep Disorder

Drugs mentioned

• NUVIGIL (armodafinil)

Snippet

Sponsor: Cephalon | Conditions: Excessive Daytime Sleepiness, Narcolepsy | Phase 3 | Status: COMPLETED | Results posted: 2010-03-31